Fierce Pharma’s 2023 Top 10 Upcoming Drug Launches

Syringe with glass vials and medications pills drug

Fierce Pharma has just released their top 10 list of drug launches to watch in 2023. At the top of the list is lecanemab (Leqembi) Eisei and Biogen’s Alzheimer’s drug, which just entered the market this week under provisional approval. Next is SRP-9001, a gene therapy targeting Duchenne muscular dystrophy (DMD), a life-threatening progressive genetic condition.

According to , “Unlike Sarepta’s other approved drugs, SRP-9001 works as a gene therapy and is designed to deliver the microdystrophin-encoding gene into muscle tissue to prompt production of the microdystrophin protein. Patients with DMD have a mutation in the DMD gene and can’t make the protein on their own, leading to a progressive loss of muscle strength. Though it could not be used by all patients, a gene therapy would be a vast improvement on the current drugs on the market. The promise of this therapy area remains high in and of itself as well as for future development, hence its high place on Evaluate’s list.”

To read more, click here.

(Source: Fierce Pharma, February 6^th, 2023)